PMID- 27542077
OWN - NLM
STAT- MEDLINE
DCOM- 20170713
LR  - 20220330
IS  - 1651-2251 (Electronic)
IS  - 0001-6489 (Linking)
VI  - 137
IP  - 1
DP  - 2017 Jan
TI  - The role of long non-coding RNA HOTAIR in the progression and development of 
      laryngeal squamous cell carcinoma interacting with EZH2.
PG  - 90-98
AB  - CONCLUSIONS: The aberrant expression of long non-coding RNA HOTAIR and 
      transmethylase EZH2 played important roles in the progression and development of 
      laryngeal squamous cell carcinoma (LSCC). OBJECTIVES: This research was aimed to 
      explore the expression and correlation with clinicopathological characteristics 
      of HOTAIR and EZH2 in LSCC, and to evaluate the function of the two in regulating 
      the proliferation and cis-platinum resistance processes of LSCC. METHODS: 
      Quantitative real time-PCR (qPCR) was conducted to measure the expression of 
      HOTAIR and EZH2 in tissue samples. Clinicopathological features were collected 
      and statistically analyzed combining with the expression of HOTAIR and EZH2. The 
      variance of EZH2 with down-regulating HOTAIR was measured by qPCR. CCK-8 
      proliferation test was conducted to detect the proliferation feature in LSCC 
      cells. After cultured with a series of cis-platinum concentrations for 24 h, cell 
      viability was detected using CCK-8 assay, and the inhibition rates were 
      calculated. RESULTS: HOTAIR and EZH2 were over-expressed in LSCC tissue. The 
      higher expression was significantly related to T phase, pathological grades, and 
      risk of lymphatic metastasis of LSCC. Suppressing HOTAIR expression stimulated 
      EZH2 expressing, promoted the proliferation of AMC-HN8 cells, and increased the 
      sensitivity to cis-platinum of the LSCC cells.
FAU - Zheng, Juan
AU  - Zheng J
AD  - a Department of Otorhinolaryngology Head and Neck Surgery , Shanghai Key Clinical 
      Disciplines of Otorhinolaryngology, Eye, Ear, Nose & Throat Hospital, Fudan 
      University , Shanghai , PR China.
FAU - Xiao, Xiyan
AU  - Xiao X
AD  - a Department of Otorhinolaryngology Head and Neck Surgery , Shanghai Key Clinical 
      Disciplines of Otorhinolaryngology, Eye, Ear, Nose & Throat Hospital, Fudan 
      University , Shanghai , PR China.
FAU - Wu, Chunping
AU  - Wu C
AD  - a Department of Otorhinolaryngology Head and Neck Surgery , Shanghai Key Clinical 
      Disciplines of Otorhinolaryngology, Eye, Ear, Nose & Throat Hospital, Fudan 
      University , Shanghai , PR China.
FAU - Huang, Jiameng
AU  - Huang J
AD  - a Department of Otorhinolaryngology Head and Neck Surgery , Shanghai Key Clinical 
      Disciplines of Otorhinolaryngology, Eye, Ear, Nose & Throat Hospital, Fudan 
      University , Shanghai , PR China.
FAU - Zhang, Yanping
AU  - Zhang Y
AD  - b Laboratory of Eye, Ear, Nose & Throat Hospital , Fudan University , Shanghai , 
      PR China.
FAU - Xie, Ming
AU  - Xie M
AD  - a Department of Otorhinolaryngology Head and Neck Surgery , Shanghai Key Clinical 
      Disciplines of Otorhinolaryngology, Eye, Ear, Nose & Throat Hospital, Fudan 
      University , Shanghai , PR China.
FAU - Zhang, Ming
AU  - Zhang M
AD  - a Department of Otorhinolaryngology Head and Neck Surgery , Shanghai Key Clinical 
      Disciplines of Otorhinolaryngology, Eye, Ear, Nose & Throat Hospital, Fudan 
      University , Shanghai , PR China.
FAU - Zhou, Liang
AU  - Zhou L
AD  - a Department of Otorhinolaryngology Head and Neck Surgery , Shanghai Key Clinical 
      Disciplines of Otorhinolaryngology, Eye, Ear, Nose & Throat Hospital, Fudan 
      University , Shanghai , PR China.
LA  - eng
PT  - Journal Article
DEP - 20160819
PL  - England
TA  - Acta Otolaryngol
JT  - Acta oto-laryngologica
JID - 0370354
RN  - 0 (Antineoplastic Agents)
RN  - 0 (HOTAIR long untranslated RNA, human)
RN  - 0 (RNA, Long Noncoding)
RN  - EC 2.1.1.43 (EZH2 protein, human)
RN  - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Carcinoma, Squamous Cell/drug therapy/*metabolism/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cisplatin/therapeutic use
MH  - Disease Progression
MH  - Drug Resistance, Neoplasm
MH  - Enhancer of Zeste Homolog 2 Protein/*metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Laryngeal Neoplasms/drug therapy/*metabolism/pathology
MH  - RNA, Long Noncoding/*metabolism
OTO - NOTNLM
OT  - Clinicopathological characteristics
OT  - cis-platinum resistance
OT  - down-regulation
OT  - inconsistence
OT  - proliferation
EDAT- 2016/08/20 06:00
MHDA- 2017/07/14 06:00
CRDT- 2016/08/20 06:00
PHST- 2016/08/20 06:00 [pubmed]
PHST- 2017/07/14 06:00 [medline]
PHST- 2016/08/20 06:00 [entrez]
AID - 10.1080/00016489.2016.1214982 [doi]
PST - ppublish
SO  - Acta Otolaryngol. 2017 Jan;137(1):90-98. doi: 10.1080/00016489.2016.1214982. Epub 
      2016 Aug 19.